Partnerships
Hansa Biopharma looks for strategic partnerships to advance healthcare in areas of high unmet need.
By partnering with players at the forefront of innovation we aim to couple our extensive expertise in biotechnology, immunology (particularly in the areas of autoimmune diseases and transplantation), pharmacology, non-clinical and clinical development of therapeutics, and mechanistic and structural approaches related to humoral immunity, and maximize the potential of our technology platform.
Partnering model
Our partnership model is focused in three key areas – drug discovery and development, commercialization and distribution / licensing.
Want to learn more? Email us at bd@hansabiopharma.com.
Current partners
Sarepta Therapeutics
In 2020, Hansa formed an exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as a potential pre-treatment prior to the administration of gene therapy for Duchenne muscular dystrophy and Limb-girdle muscular dystrophy in patients with antibodies to adeno-associated virus (AAV).
AskBio
In 2022, Hansa and AskBio partnered to evaluate the use of imlifidase as a pre-treatment prior to the administration of gene therapy in Pompe disease in a preclinical and clinical feasibility program for patients with antibodies to adeno-associated virus (AAV).
Généthon
Hansa and Généthon formed a research and development collaboration in 2023 to assess the use of imlifidase as a pre-treatment preceding the administration of Généthon’s gene therapy in Crigler-Najjar syndrome in patients with antibodies to adeno-associated virus (AAV). A preclinical and clinical feasibility program will evaluate the safety and efficacy of imlifidase in this setting.
Medison Pharma
Together with Medison, Hansa is collaborating to commercialize imlifidase in Central Eastern Europe and Israel. Formed in 2021, the commercialization partnership will expand access to imlifidase pending marketing authorization in certain regions.